Sasha Stafford focuses on the architectural design of injectable hydrogels and multifunctional nanoparticle systems optimized for the controlled, localized release of therapeutic payloads. By utilizing the WDVAX platform and novel co-delivery of disparate therapeutic moieties in Glioblastoma Multiforme (GBM) models, his research demonstrates how engineered drug delivery depots can  elicit potent immunomodulation and enhance the PharmacoKinetic (PK) profile of encapsulated therapeutic agents. This translational trajectory spans from rigorous preclinical validation to the achievement of critical regulatory milestones. By bridging the gap between bench-top discovery and clinical implementation, this work provides a framework for multi-sector collaborations aimed at reducing patient morbidity and mortality through high-precision, biocompatible drug delivery technologies.